Compare Abeona Therapeutics Inc (ABEO) vs American States Water Company (AWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American States Water Company — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while American States Water Company trades at $83.83 (market cap $3.26B). The key difference: American States Water Company is far larger — about 8.7× Abeona Therapeutics Inc's market cap, and American States Water Company pays a 2.42% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AWR | |
|---|---|---|
Market Cap | $373.32M | $3.26B |
Sector | Health | Utilities |
52-Week High | $7.23 | $84.76 |
52-Week Low | $4.17 | $70.10 |
Enterprise Value | $228.22M | $4.17B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
American States Water (AWR) trades at $83.14, down 1.91% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.66% net margins and consistent dividend growth, though recent earnings show mixed quarterly performance. Recent news highlights AWR's defensive utility characteristics and completion of a $200 million equity offering program.
AWR presents a stable investment case with reliable dividend income and utility sector defensiveness, though valuation appears elevated at 24.24 P/E. Key risks include regulatory rate pressures and execution of capital investments. Analyst sentiment remains cautious with only 20% buy ratings, suggesting limited near-term upside potential despite the company's operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
